Aneurysmal Subarachnoid HemorrhageNCT02129413
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
A study testing Delta system in people with Aneurysmal Subarachnoid Hemorrhage and Cerebral Vasospasm, run by Samson NeuroSciences at 7 sites in 3 countries.
Trial summary
The purpose of this study is to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
- What is being tested?
- Delta system
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 23 participants
- Where
- 7 sitesin 3 countries
- Study dates
- May 2014to Aug 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female older than 18 years of age and no more than 75 years of age.
- aSAH patients with secured aneurysm.
- Patient has cerebral vasospasm and is anesthetized and intubated.
- Cerebral vasospasm is manifested by:
- Mean Flow Velocity (MFV) >120 cm/sec in the intracranial ICA (Internal carotid artery), MCA (middle cerebral artery) or ACA (anterior cerebral artery) or MFV >110 cm/sec in the PCA, or >85 cm/sec in the vertebral or basilar arteries, as measured by TCD (Trans Cranial Doppler).
- Or:
Show all 15Show fewer
- Extra/intracranial ratio for the carotid watershed (MCA, ACA, intracranial ICA)>3, or a proximal/distal ratio for the vertebrobasilar (VB) system > 2.
- Or:
- Affected/contralateral MCA MFV ratio ≥1.5. Or
- Affected / baseline MCA MFV ratio ≥1.5.
- AND:
- Vasoconstriction of at least 33% in at least one of the main cerebral arteries, measured by Angiography (Digital Subtraction Angiography (DSA) or Computed Tomography Angiography (CTA).
- Hemodynamically stable, including subjects who are treated for fever, hydrocephalus, rebleeding, infection or metabolic abnormalities and are stable.
- For pre-menopausal females - a negative pregnancy test, using an accepted method of birth control and avoid breast feeding for the duration of the trial
- A legally Authorized representative have signed informed consent.
Who cannot join
- WFNS score 5
- Unsecured aneurysm or Intracranial/SAH of other than aneurysmal origin.
- Signs attributable to serious aneurismal surgical procedure-related complications.
- Patient underwent decompressive craniectomy.
- S/p Carotid Endarterectomy, or other neck intervention.
- Known carotid body tumor, past or present.
Show all 15Show fewer
- Hemodynamic instability due to cardiac arrhythmia or due to any other cause.
- Had a myocardial infarction, unstable angina or syncope, congestive heart failure that require hospitalization or ejection fraction ≤ 40% within the past 3 months. Note: Elevated Troponin is expected after aSAH and will not exclude patients.
- Had a stroke, within the past 1 year or transient ischemic attack at the last 3 months.
- Any anatomical variation or thrombotic finding that according to the physician judgment is not eligible.
- Renal insufficiency (Creatinine X2 of the normal).
- Allergic to contrast media with no response to steroid pretreatment.
- Are unable or unwilling to fulfill the protocol follow-up requirements
- Are enrolled in another concurrent clinical trial, without prior approval of Samson NS and the PI.
- Have an uncontrolled comorbid medical condition that would adversely affect their health if they are enrolled.
Trial locations and contacts
7 sites in 3 countries.
7 sites in 3 countries
Germany4 sites, 4 recruiting
- Recruiting
Charite Universitätsmedizin Berlin
Berlin, 13353
Peter Vajkoczy, Prof., peter.vajkoczy@charite.de
- Recruiting
Johann Wolfgang Goethe-Universität
Frankfurt, D-60528
Christian Senft, MD, PhD., c.senft@med.uni-frankfurt.de
- Recruiting
Neurochirurgische Universitätsklinik Georg-August-Universität
Göttingen, 37075
Veit Rohde, Prof, veit.rohde@med.uni-goettingen.de
- Recruiting
University of Heidelberg
Heidelberg, D-69120
Oliver Sakowitz, Prof, oliver.sakowitz@med.uni-heidelberg.de
Czechia2 sites, 2 recruiting
- Recruiting
FN Brno
Jihlavská 20 625 00 Brno
Martin Smrcka, Prof, msmrcka@fnbrno.cz
- Recruiting
UVN Praha Central Military Hospital
Prague, 169 02
Vladimir Beneš, Prof., vladimir.benes@uvn.cz
Israel1 site, 1 recruiting
- Recruiting
The Chaim Sheba Medical Center, Department of Neurosurgery
Tel HaShomer, 52621
Sagi Harnof, Dr., 972-3-5302650, Sagi.harnof@sheba.health.gov.il
About this study
Official title: Safety and Performance of the Delta System in the Treatment of Vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH) Patients
The purpose of this study is to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients.
Read the detailed description
The Delta system is intended to deliver electrical modulation signal to the carotid body, to result in cerebral vasodilation and blood flow augmentation in the brain, for treatment of patients suffering from vasospasm post aSAH.
In this clinical trial the Delta system in intended to be used on patients who have their ruptured aneurysm secured, hospitalized in the neuro ICU (Intensive Care Unit) and are anesthetized and intubated, diagnose as suffer from cerebral vasospasm, who fulfill all the inclusion criteria and none of the exclusion as detailed in the study protocol.
The system is intended to be used for up to 7 days under hospital supervision that is routinely provided for stabilizing patients following SAH and securing aneurysms. Follow up period is 30 days after end of treatment.
The Delta system is comprised from two main elements: Electrical Stimulation Unit (ESU) and Delivery kit.The ESU is a reusable external autonomic stimulator unit, cable and graphic user interface (GUI) software based on a PC tablet. The delivery kit is a disposable stimulating leads shaft and accessories.
The procedure includes insertion of the leads shaft over a guiding needle via patient neck, so electrodes are positioned adjacent the carotid bodies. Therapy parameters are set by the physician and monitoring is continued during patient hospitalization to determine when therapy can be discontinued and shaft removed.
Twenty three (23) patients will be recruited to the study, including 3 roll-in patients. The study is an open label, uncontrolled, non-randomized, multicenter feasibility study. This study will recruit male and female adult patients with aSAH secondary to rupture of an aneurysm, secured by coiling or clipping, and in WFNS grades I-IV. Only anesthetized and intubated patients will be recruited for the study.
This study evaluates the safety and performance of the Delta system. The potential benefits and risks of participation in this study are clearly identified in the informed consent form and are to be explained to the subject prior to participating in the study.
Study treatment - The Delta system is inserted by minimally exposure of the carotid bifurcation. The system electrically stimulates the carotid body chemoreceptors, aiming to achieve sustainable cerebral vasodilation for inducing enhancement of cerebral perfusion and thereby minimizing ischemia and consequently prevent delayed neurological deficit. Treatment with the delta system is intended for up to seven (7) days.
Manufacturing and assembling the Delta system is done in certified facilities. Further information and complete details regarding device materials, specifications, design, quality assurance, etc. can be found in the Investigator's Brochure.
Risk to benefit rational - reverse vasospasm and increase cerebral blood flow (CBF) is the major component of cerebral perfusion augmentation, results in reducing the rate of vasospasm complication. The Delta system may provide vasospasm subjects with a novel treatment option. Based on the Delta system design, the extensive pre-clinical tests conducted with the system and the comparison to other similar devices and alternative treatments, the company believes that the system is safe for use and beneficial for reduction of delayed cerebral ischemia complication that are vasospasm related.
Statistical analysis plan - Sample size for this study is determined by the secondary end point.
Sample size of N=20 achieves:
- 88% power to detect CBF decrease of ≥ 15% in at least one of the affected cerebral arteries measured by TCD.
- 88% power to detect increase in artery diameter of ≥15% in at least one of the affected main cerebral arteries measured by DSA or CTA.
- 99% power to detect CBF increase of ≥20% measured by CerOx monitor system or Licox® monitoring system.
All with an estimated standard deviation of 0.2 and with alpha of 0.05, using a one-sample t-test analysis. The sample size also serves the qualitative analysis of the primary end point.
A t-test is any statistical hypothesis test in which the test statistic follows a Student's t distribution if the null hypothesis is supported. It can be used to determine if two sets of data are significantly different from each other for continues parameters (such as artery diameter) , and is most commonly applied when the test statistic would follow a normal distribution if the value of a scaling term in the test statistic were known. The estimation for the significant clinical difference as well as the assumed standard deviation was based on previous experience with the device. When the scaling term is unknown and is replaced by an estimate based on the data, the test statistic (under certain conditions) follows a Student's t distribution.
Data management plan - Data management will be directly provided or contracted by the sponsor and compliant to the requirements of ISO 14155:2011. The Sponsor or its designee will provide the investigator with a Case Report Form (CRF) booklet for each subject enrolled in the study and will train the site personnel in the correct manner of recording data. The appropriate CRFs will be completed and signed by the Investigator as appropriate. All CRFs will be completed in a legible manner in blue or black ink. Any corrections will be made by drawing a single line through the incorrect entry, entering the correct information, and initialing and dating the change. Data entry boxes or spaces should not be left blank, but instead should indicate: NA for not applicable, ND for not done or "-"for missing or not available data. The original signed forms, not copies, will be returned to the Sponsor. All clinical data generated in the study will be submitted to the Sponsor or its designee for quality assurance review, data entry, and statistical analysis. All forms will be reviewed for completeness. Any recording errors will be corrected by contact with the appropriate clinical site. Double-entry routines will be utilized to reduce data entry errors, and computerized editing routines will be used to identify unusual data entries for verification prior to statistical analysis.
- Being tested
- Delta system
- Keywords
- Aneurysmal subarachnoid hemorrhage, Subarachnoid hemorrhage, Cerebral vasospasm, Ruptured aneurysm, Delayed Cerebral Ischemia, Delayed Ischemic Deficit, Delayed ischemic neurological deficit, Neurostimulation, Carotid body
- Medical subject headings
- Subarachnoid Hemorrhage, Vasospasm, Intracranial, Aneurysm, Ruptured
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Delta systemDevice
| Study group | Role | What they receive |
|---|---|---|
| Delta system treatment | Experimental | Not described Receives: Device: Delta system |
What is being measured
The primary outcome is the main question the study is designed to answer.
Device or procedure related (possibly, probably, or definitely) serious adverse events rate, from the treatment period and up to 30 days.
Measured: 30 days
Secondary outcomes (6)
Decrease Mean Flow Velocity (MFV) of ≥15% below the maximal MVF measured prior to treatment, in at least one of the affected cerebral arteries, in at least one measuring during treatment
Measured: 7 days
Increase diameter of ≥15% in at least one of the affected main cerebral arteries, measured by Digital Subtraction Angiography (DSA) or Computed Tomography Angiography (CTA)
Measured: 7 days
Increase of ≥20% in PbtO2 above baseline prior to treatment measured by Licox® monitoring system during treatment
Measured: 7 days
Increase of ≥20% in CBF above baseline prior to treatment measured by the CerOx monitor system during treatment
Measured: 7 days
Mechanical performance of the Delta system
Lead shaft mechanical performance (e.g insertion, positioning/re positioning, fixation and retrieval) will be quantitatively measured
Measured: 7 days
Electrical performance of the Delta system
Electrical performance of the electrical stimulation unit will be quantitatively measured
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2014 (estimated)
- Study startMay 2014
- Primary completionAug 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aneurysmal Subarachnoid HemorrhageStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 23 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Samson NeuroSciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Peter Vajkoczy, Prof., Principal investigator, Charite - Universitätsmedizin, Department of Neurosurgery (Campus Virchow Klinikum), Berlin 113353, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02129413
- Sponsor's protocol ID
- DLT-CL-PR-01
- Status last verified
- Apr 2014
- First submitted
- 24 Apr 2014
- Last updated
- 5 Feb 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Performance of the Delta System in the Treatment of Vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH) Patients
- ClinicalTrials.gov ID
- NCT02129413
- Acronym / sponsor ID
- DLT-CL-PR-01
- Keywords
- Aneurysmal subarachnoid hemorrhage, Subarachnoid hemorrhage, Cerebral vasospasm, Ruptured aneurysm, Delayed Cerebral Ischemia, Delayed Ischemic Deficit, Delayed ischemic neurological deficit, Neurostimulation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 23 participants (estimated)
- Lead sponsor
- Samson NeuroSciencesIndustry (pharma, biotech, devices)
- Study start
- May 2014
- Primary completion
- Aug 2015 (estimated)
- First posted
- 2 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients.
Detailed description
The Delta system is intended to deliver electrical modulation signal to the carotid body, to result in cerebral vasodilation and blood flow augmentation in the brain, for treatment of patients suffering from vasospasm post aSAH.
In this clinical trial the Delta system in intended to be used on patients who have their ruptured aneurysm secured, hospitalized in the neuro ICU (Intensive Care Unit) and are anesthetized and intubated, diagnose as suffer from cerebral vasospasm, who fulfill all the inclusion criteria and none of the exclusion as detailed in the study protocol.
The system is intended to be used for up to 7 days under hospital supervision that is routinely provided for stabilizing patients following SAH and securing aneurysms. Follow up period is 30 days after end of treatment.
The Delta system is comprised from two main elements: Electrical Stimulation Unit (ESU) and Delivery kit.The ESU is a reusable external autonomic stimulator unit, cable and graphic user interface (GUI) software based on a PC tablet. The delivery kit is a disposable stimulating leads shaft and accessories.
The procedure includes insertion of the leads shaft over a guiding needle via patient neck, so electrodes are positioned adjacent the carotid bodies. Therapy parameters are set by the physician and monitoring is continued during patient hospitalization to determine when therapy can be discontinued and shaft removed.
Twenty three (23) patients will be recruited to the study, including 3 roll-in patients. The study is an open label, uncontrolled, non-randomized, multicenter feasibility study. This study will recruit male and female adult patients with aSAH secondary to rupture of an aneurysm, secured by coiling or clipping, and in WFNS grades I-IV. Only anesthetized and intubated patients will be recruited for the study.
This study evaluates the safety and performance of the Delta system. The potential benefits and risks of participation in this study are clearly identified in the informed consent form and are to be explained to the subject prior to participating in the study.
Study treatment - The Delta system is inserted by minimally exposure of the carotid bifurcation. The system electrically stimulates the carotid body chemoreceptors, aiming to achieve sustainable cerebral vasodilation for inducing enhancement of cerebral perfusion and thereby minimizing ischemia and consequently prevent delayed neurological deficit. Treatment with the delta system is intended for up to seven (7) days.
Manufacturing and assembling the Delta system is done in certified facilities. Further information and complete details regarding device materials, specifications, design, quality assurance, etc. can be found in the Investigator's Brochure.
Risk to benefit rational - reverse vasospasm and increase cerebral blood flow (CBF) is the major component of cerebral perfusion augmentation, results in reducing the rate of vasospasm complication. The Delta system may provide vasospasm subjects with a novel treatment option. Based on the Delta system design, the extensive pre-clinical tests conducted with the system and the comparison to other similar devices and alternative treatments, the company believes that the system is safe for use and beneficial for reduction of delayed cerebral ischemia complication that are vasospasm related.
Statistical analysis plan - Sample size for this study is determined by the secondary end point.
Sample size of N=20 achieves:
- 88% power to detect CBF decrease of ≥ 15% in at least one of the affected cerebral arteries measured by TCD.
- 88% power to detect increase in artery diameter of ≥15% in at least one of the affected main cerebral arteries measured by DSA or CTA.
- 99% power to detect CBF increase of ≥20% measured by CerOx monitor system or Licox® monitoring system.
All with an estimated standard deviation of 0.2 and with alpha of 0.05, using a one-sample t-test analysis. The sample size also serves the qualitative analysis of the primary end point.
A t-test is any statistical hypothesis test in which the test statistic follows a Student's t distribution if the null hypothesis is supported. It can be used to determine if two sets of data are significantly different from each other for continues parameters (such as artery diameter) , and is most commonly applied when the test statistic would follow a normal distribution if the value of a scaling term in the test statistic were known. The estimation for the significant clinical difference as well as the assumed standard deviation was based on previous experience with the device. When the scaling term is unknown and is replaced by an estimate based on the data, the test statistic (under certain conditions) follows a Student's t distribution.
Data management plan - Data management will be directly provided or contracted by the sponsor and compliant to the requirements of ISO 14155:2011. The Sponsor or its designee will provide the investigator with a Case Report Form (CRF) booklet for each subject enrolled in the study and will train the site personnel in the correct manner of recording data. The appropriate CRFs will be completed and signed by the Investigator as appropriate. All CRFs will be completed in a legible manner in blue or black ink. Any corrections will be made by drawing a single line through the incorrect entry, entering the correct information, and initialing and dating the change. Data entry boxes or spaces should not be left blank, but instead should indicate: NA for not applicable, ND for not done or "-"for missing or not available data. The original signed forms, not copies, will be returned to the Sponsor. All clinical data generated in the study will be submitted to the Sponsor or its designee for quality assurance review, data entry, and statistical analysis. All forms will be reviewed for completeness. Any recording errors will be corrected by contact with the appropriate clinical site. Double-entry routines will be utilized to reduce data entry errors, and computerized editing routines will be used to identify unusual data entries for verification prior to statistical analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Delta system treatment | Experimental | Device: Delta system |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Male and female older than 18 years of age and no more than 75 years of age.
- aSAH patients with secured aneurysm.
- Patient has cerebral vasospasm and is anesthetized and intubated.
- Cerebral vasospasm is manifested by:
- Hemodynamically stable, including subjects who are treated for fever, hydrocephalus, rebleeding, infection or metabolic abnormalities and are stable.
Key exclusion criteria (15 listed)
- WFNS score 5
- Unsecured aneurysm or Intracranial/SAH of other than aneurysmal origin.
- Signs attributable to serious aneurismal surgical procedure-related complications.
- Patient underwent decompressive craniectomy.
- S/p Carotid Endarterectomy, or other neck intervention.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Delta system | Device | Delta system treatment |
Primary outcome
Device or procedure related (possibly, probably, or definitely) serious adverse events rate, from the treatment period and up to 30 days.
Time frame: 30 days
6 secondary outcomes
Decrease Mean Flow Velocity (MFV) of ≥15% below the maximal MVF measured prior to treatment, in at least one of the affected cerebral arteries, in at least one measuring during treatment
Time frame: 7 days
Increase diameter of ≥15% in at least one of the affected main cerebral arteries, measured by Digital Subtraction Angiography (DSA) or Computed Tomography Angiography (CTA)
Time frame: 7 days
Increase of ≥20% in PbtO2 above baseline prior to treatment measured by Licox® monitoring system during treatment
Time frame: 7 days
Increase of ≥20% in CBF above baseline prior to treatment measured by the CerOx monitor system during treatment
Time frame: 7 days
Mechanical performance of the Delta system
Time frame: 7 days
Electrical performance of the Delta system
Time frame: 7 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2015.
Related trials for Aneurysmal Subarachnoid Hemorrhage
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage
RecruitingPhase 2
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Headache
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Vajkoczy, Prof. principal investigator
Charite - Universitätsmedizin, Department of Neurosurgery (Campus Virchow Klinikum), Berlin 113353, Germany
7 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Delta system in people with Aneurysmal Subarachnoid Hemorrhage and Cerebral Vasospasm, run by Samson NeuroSciences at 7 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Feb 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Germany, Czechia, Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ronnie Levy (+97297745606, clinical.affairs@samsonneuro.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Device or procedure related (possibly, probably, or definitely) serious adverse events rate, from the treatment period and up to 30 days. (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2015.